Boehringer Mannheim Gmbh

Hoffmann-la Roche Inc.

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

Frieder Bauss

Christos Tsaklakidis

Angelika Esswein

Elmar Bosies

Bernhard Pichler

Stephen Turley

Gerd Zimmermann

Birgit Bossenmaier

Harald Zilch

Marlene Thomas

Thomas Friess

Max Hasmann

Christian Gerdes

Martin Weisser

Andreas A Kurth

Drasko Brkovic

Steven Turley

The present invention relates to the combination therapy of anti-HER3 antibodies with certain anti-HER antibodies.

Combination therapy of anti-HER3 antibodies

The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficious daily dose of a bisphosphonic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients thereof and administering the dose at a period of one two or three consecutive days per month.

Method of treatment using bisphosphonic acid

The invention relates to use of ibandronic acid (1-hydroxy-3-(N-methyl-N-pentyl)aminopropyl-1,1-diphosphonic acid) or physiologically compatible salts or esters thereof for improving the osseointegration of cement-free anchored endoprostheses. Ibandronate or salts thereof is applied for a short time immediately after insertion of an endoprosthesis, with the surprising result that secondary stability of the implant is obtained in only 5 weeks or less after the operation.

Use of ibandronate for promoting osseointegration of endoprostheses

The invention relates to use of diphosphonic acids or physiologically compatible salts or esters thereof for preventive treatment of disturbances to ossary mineralization which may occur after operative extension of the urine bladder by augmentation plasties or replacement of the urine bladder by replacement plasties but often do not appear until years after the operation.

Use of diphosphonic acids or the physiologically acceptable salts or esters thereof in the preventive treatment of after-effects resulting from enlargement or replacement of the bladder

2,4-diphosphonoglutaric acid derivatives, processes for their production

Phosphosuccinic acid derivatives, processes for the production thereof

Compounds of the formula I ##STR1## in which R signifies a possibly substituted amino group of the general formula --NR.sup.1 R.sup.2, whereby, independently of one another, R.sup.1 and R.sup.2 each signify hydrogen, lower alkyl, lower alkenyl or lower alkynyl or R represents a saturated, unsaturated or aromatic heterocyclic ring which can possibly be substituted once or twice by lower alkyl or halogen, alk signifies a valency bond, a methylene, a saturated or unsaturated, straight-chained or branched alkylene chain with 2-6 carbon atoms and R.sup.3, R.sup.4 and R.sup.5, in each case independently of one another, signify hydrogen, lower alkyl or benzyl, as well as their pharmacologically acceptable salts and enantiomers, whereby, for the case that R.sup.3 =R.sup.4 =R.sup.5 =CH.sub.3 and alk signifies a valency bond, R cannot be the dimethylamino group, processes for their preparation and medicaments which contain these compounds for the treatment of calcium metabolism diseases.

Phosphonic acid compound containing heterocyclic substituents,

Acyclic amidine group-containing diphosphonic acid derivatives,

Phosphonosuccinic acid derivatives, processes for their preparation and

Disphosphonic acid derivatives, processes for their production and

Growing community of inventors

Neuhofen, Germany

Frieder Bauss